Table 1 Sample characteristics by diagnosis, sex, and amyloid status
Normal cognition | Early mild cognitive impairment | |||||||
|---|---|---|---|---|---|---|---|---|
Female (n = 154) | Male (n = 131) | Female (n = 205) | Male (n = 252) | |||||
Florbetapir-negative | Florbetapir-positive | Florbetapir-negative | Florbetapir-positive | Florbetapir-negative | Florbetapir-positive | Florbetapir-negative | Florbetapir-positive | |
Demographics | ||||||||
No. of subjects | 91 | 63 | 100 | 31 | 93 | 112 | 114 | 138 |
Age, years | 70.8 (5.6) | 72.4 (5.0) | 72.3 (6.2) | 77.8 (5.8) | 69.5 (8.3) | 70.8 (7.1) | 69.2 (7.4) | 73.7 (6.4) |
Education, years | 16.5 (2.5) | 15.5 (2.6) | 17.2 (2.3) | 17.6 (2.4) | 15.8 (2.3) | 15.6 (2.8) | 16.8 (2.5) | 16.5 (2.7) |
White, % | 92.3 | 93.7 | 89 | 87.1 | 90.3 | 92 | 92.1 | 96.4 |
Hispanic, % | 8.8 | 4.8 | 3 | 0 | 6.5 | 3.6 | 3.5 | 2.2 |
Cognition | ||||||||
Modified MoCA | 23.5 (1.6) | 22.3 (1.7) | 23.4 (1.7) | 23.0 (1.6) | 22.6 (2.1) | 21.8 (2.4) | 22.6 (2.0) | 21.9 (2.5) |
RAVLT Total Learning | 48.8 (8.9) | 47.0 (8.3) | 44.4 (11.5) | 37.7 (8.8) | 45.0 (11.6) | 37.6 (10.7) | 37.2 (9.9) | 32.0 (8.9) |
RAVLT Delayed Recall | 8.9 (3.4) | 7.8 (3.6) | 7.0 (4.5) | 5.2 (3.1) | 7.4 (4.5) | 4.3 (4.2) | 5.0 (3.7) | 3.5 (3.2) |
Brain volumea | ||||||||
No. of subjects | 59 | 34 | 70 | 16 | 77 | 84 | 86 | 100 |
Left, raw, mm3 | 3640.458 (408.312) | 3626.059 (451.953) | 3891.829 (495.200) | 3716.563 (338.556) | 3530.481 (502.509) | 3339.369 (516.286) | 3724.186 (579.737) | 3438.300 (541.483) |
Right, raw, mm3 | 3727.322 (444.720) | 3718.941 (450.135) | 3991.514 (460.636) | 3712.375 (348.348) | 3631.662 (493.285) | 3338.345 (552.385) | 3822.256 (612.419) | 3562.970 (500.952) |
Total ICV, raw, mm3 | 1.41 × 106 (102,176.7) | 1.41 × 106 (122,896.4) | 1.57 × 106 (135,998.0) | 1.58 × 106 (151,662.0) | 1.42 × 106 (121,471.7) | 1.41 × 106 (108,602.5) | 1.58 × 106 (127,438.3) | 1.61 × 106 (149,837.7) |
APOE ε4 carrier status | ||||||||
ε4 allele carriers, n | 23 | 29 | 17 | 15 | 19 | 76 | 32 | 93 |